Specific mutations of hepatitis B virus in plasma predict liver cancer development
- PMID: 14990795
- PMCID: PMC373504
- DOI: 10.1073/pnas.0308232100
Specific mutations of hepatitis B virus in plasma predict liver cancer development
Abstract
A major risk factor for hepatocellular carcinoma (HCC) is hepatitis B virus (HBV), whose pathogenesis is exacerbated by the acquisition of mutations that accelerate carcinogenesis. We examined, with mass spectrometry, the temporality of an HBV 1762(T)/1764(A) double mutation in plasma and tumors. Initial studies found that 52 of 70 (74.3%) tumors from patients residing in Qidong, People's Republic of China, contained this HBV mutation. Paired plasma samples were available for six of the tumor specimens; four tumors had the HBV 1762(T)/1764(A) mutation, whereas three of the paired plasma samples were also positive. The potential predictive value of this biomarker was explored by using stored plasma samples from a study of 120 residents of Qidong who had been monitored for aflatoxin exposure and HBV infection. After 10 years of passive follow-up, there were six cases of major liver disease including HCC (four cases), hepatitis (one case), and cirrhosis (one case). All six cases had detectable levels of the HBV 1762(T)/1764(A) mutation up to 8 years before diagnosis. Finally, 15 liver cancers were selected from a prospective cohort of 1,638 high-risk individuals in Qidong on the basis of available plasma samples spanning the years before and after diagnosis. The HBV 1762(T)/1764(A) mutation was detected in 8 of the 15 cases (53.3%) before cancer. The persistence of detection of this mutation was statistically significant (P = 0.022, two-tailed). We therefore found that a prediagnosis biomarker of specific HBV mutations can be measured in plasma and suggest this marker for use as an intermediate endpoint in prevention and intervention trials.
Figures
Similar articles
-
Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.Carcinogenesis. 2011 Jun;32(6):860-5. doi: 10.1093/carcin/bgr055. Epub 2011 Apr 7. Carcinogenesis. 2011. PMID: 21474708 Free PMC article.
-
Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry.Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1213-8. doi: 10.1158/1055-9965.EPI-06-0905. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17548687
-
Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.World J Gastroenterol. 2011 Oct 14;17(38):4258-70. doi: 10.3748/wjg.v17.i38.4258. World J Gastroenterol. 2011. PMID: 22090781 Free PMC article. Review.
-
Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China.J Hepatol. 2008 Nov;49(5):718-25. doi: 10.1016/j.jhep.2008.06.026. Epub 2008 Jul 24. J Hepatol. 2008. PMID: 18801591
-
Hepatitis B viral load affects prognosis of hepatocellular carcinoma.World J Gastroenterol. 2014 Sep 14;20(34):12039-44. doi: 10.3748/wjg.v20.i34.12039. World J Gastroenterol. 2014. PMID: 25232241 Free PMC article. Review.
Cited by
-
Detection of hepatitis B virus A1762T/G1764A mutant by amplification refractory mutation system.Braz J Infect Dis. 2014 May-Jun;18(3):261-5. doi: 10.1016/j.bjid.2013.09.005. Epub 2014 Jan 3. Braz J Infect Dis. 2014. PMID: 24389280 Free PMC article.
-
Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.Carcinogenesis. 2011 Jun;32(6):860-5. doi: 10.1093/carcin/bgr055. Epub 2011 Apr 7. Carcinogenesis. 2011. PMID: 21474708 Free PMC article.
-
DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.Analyst. 2014 Jun 7;139(11):2754-63. doi: 10.1039/c4an00215f. Analyst. 2014. PMID: 24759937 Free PMC article.
-
Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies.Chin J Cancer Res. 2015 Oct;27(5):497-508. doi: 10.3978/j.issn.1000-9604.2015.10.05. Chin J Cancer Res. 2015. PMID: 26543337 Free PMC article.
-
Molecular biology of the hepatitis B virus for clinicians.J Clin Exp Hepatol. 2012 Dec;2(4):353-65. doi: 10.1016/j.jceh.2012.10.003. Epub 2012 Oct 18. J Clin Exp Hepatol. 2012. PMID: 25755457 Free PMC article. Review.
References
-
- Wang, X. W., Hussain, P., Huo, T.-I., Wu, C.-G., Forgues, M., Hofseth, L. J., Brechot, C. & Harris C. C. (2002) Toxicology 181-182, 43-47. - PubMed
-
- Kew, M. C. (2002) Toxicolology 181-182, 35-38. - PubMed
-
- Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N. & Groopman, J. D. (1994) Cancer Epidemiol. Biomarkers Prev. 3, 3-10. - PubMed
-
- Kensler, T. W., Qian, G.-S., Chen, J.-G. & Groopman, J. D. (2003) Nat. Cancer Rev. 3, 321-329. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical